Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 446 participants.
Also called NCT03241459
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 446 participants
- Sponsor
- SurModics, Inc.
- Registry
-
NCT03241459
-
- Other papers using this trial's data
- Editor's Choice - Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: 24 Month Outcomes of the Randomised TRANSCEND Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Czechia, Germany, Italy, Latvia, New Zealand
- Registry status
- Completed
Technical summary
Registry record NCT03241459. Randomized; single masking; primary purpose treatment. Start 2017-10-23 (actual); primary completion 2020-09-15 (actual). Results posted on 2024-04-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
- Acronym
- TRANSCEND
- Condition
- Peripheral Arterial Disease
- Condition
- Peripheral Vascular Disease
- Condition
- Artery Disease, Peripheral
- Condition
- Femoropopliteal Artery Occlusion
- Intervention (Device)
- Surmodics SurVeil DCB
- Intervention (Device)
- Medtronic IN.PACT Admiral DCB
- Lead sponsor
- SurModics, Inc.
Record details
- Record id
cardio:ct-nct03241459- Content hash
d61e55e39a082b380fd497ccf3a2582eb12ec5dd2cda2d32cb17e82408ca45d4